Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerLuis Paz‐Ares, Dariusz M. Kowalski, Tibor Csőszi et al.|New England Journal of Medicine|2018Cited by 3.7k
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407Luis Paz‐Ares, Marina Chiara Garassino, Corey J. Langer et al.|Annals of Oncology|2019Cited by 105
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina Chiara Garassino, Luis Paz‐Ares, Shirish M. Gadgeel et al.|JTO Clinical and Research Reports|2022Cited by 43
Overall Survival With Second-Line Pembrolizumab in Patients With Non–Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World DataThomas Jemielita, Cong Chen, Xiaoyun Li et al.|JCO Clinical Cancer Informatics|2021Cited by 15